全文获取类型
收费全文 | 2210篇 |
免费 | 279篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 68篇 |
妇产科学 | 31篇 |
基础医学 | 136篇 |
口腔科学 | 88篇 |
临床医学 | 326篇 |
内科学 | 637篇 |
皮肤病学 | 45篇 |
神经病学 | 74篇 |
特种医学 | 311篇 |
外科学 | 201篇 |
综合类 | 25篇 |
预防医学 | 319篇 |
眼科学 | 25篇 |
药学 | 126篇 |
肿瘤学 | 88篇 |
出版年
2023年 | 48篇 |
2022年 | 15篇 |
2021年 | 16篇 |
2020年 | 43篇 |
2019年 | 25篇 |
2018年 | 59篇 |
2017年 | 34篇 |
2016年 | 53篇 |
2015年 | 60篇 |
2014年 | 103篇 |
2013年 | 132篇 |
2012年 | 45篇 |
2011年 | 58篇 |
2010年 | 80篇 |
2009年 | 93篇 |
2008年 | 67篇 |
2007年 | 96篇 |
2006年 | 88篇 |
2005年 | 66篇 |
2004年 | 69篇 |
2003年 | 41篇 |
2002年 | 52篇 |
2001年 | 54篇 |
2000年 | 47篇 |
1999年 | 56篇 |
1998年 | 68篇 |
1997年 | 93篇 |
1996年 | 85篇 |
1995年 | 63篇 |
1994年 | 67篇 |
1993年 | 54篇 |
1992年 | 30篇 |
1991年 | 26篇 |
1990年 | 44篇 |
1989年 | 61篇 |
1988年 | 53篇 |
1987年 | 49篇 |
1986年 | 46篇 |
1985年 | 37篇 |
1984年 | 22篇 |
1983年 | 24篇 |
1982年 | 29篇 |
1981年 | 33篇 |
1980年 | 20篇 |
1979年 | 16篇 |
1978年 | 8篇 |
1977年 | 19篇 |
1976年 | 18篇 |
1975年 | 12篇 |
1971年 | 5篇 |
排序方式: 共有2510条查询结果,搜索用时 0 毫秒
181.
182.
183.
184.
An emerging role for nurses is that of expert witness for medical liability cases that involve nursing care. Medical liability cases require that the trier of evidence (judge or jury) have an understanding of the facts and the relevant standards of the case for equitable resolution. The attorney, judge, or jury member may not possess the information necessary to understand the issues. Someone with the requisite knowledge and skills to review the information, interpret facts, offer an opinion about whether or not the standard of care was met, and explain this to the appropriate people is crucial for the legal system to work. If nursing care is at issue, that expert is a nurse with the appropriate knowledge, experience, and education. This report explores the role, qualifications, and expectations for nurses who serve as expert witnesses. Personal insights from the authors will provide practical information for nurses who are interested in the role. Copyright © 2001 by W.B. Saunders Company 相似文献
185.
186.
RC Johnson FRCS AR Hedges MS FRCS R Morris FFARCS JD Stamatakis MS FRCS 《International journal of clinical practice》1999,53(1):16-18
In a previous report the effectiveness of intraperitoneal bupivacaine in reducing pain following laparoscopic cholecystectomy was demonstrated. Other methods of pain relief are commonly used but none has been compared following laparoscopic cholecystectomy. In two further studies we have compared the analgesic effect of intraperitoneal bupivacaine against wound infiltration with bupivacaine, and against intraperitoneal bupivacaine with the addition of a non-steroidal anti-inflammatory drug (NSAID) in patients undergoing laparoscopic cholecystectomy. Two consecutive studies were performed. In the first, patients in group 1 were given 20 ml of 0.25% bupivacaine into the peritoneal cavity; patients in group 2 were given 20 ml of 0.25% bupivacaine injected into the trocar wounds. In the second study, patients in group 1 were given 20 ml of 0.25% bupivacaine into the peritoneal cavity; patients in group 2 were given 20 ml of 0.25% bupivacaine into the peritoneal cavity and a diclofenac suppository (100 mg) one hour before surgery. Postoperative pain was assessed with a visual analogue pain scale. There was no difference in pain scores in the two groups in either study. Intraperitoneal bupivacaine is as effective as wound infiltration. The addition of an NSAID makes no difference in the reduction of postoperative pain following laparoscopic cholecystectomy. 相似文献
187.
188.
A Oros MJ Houtman P Neco AM Gomez S Rajamani P Oosterhoff NJ Attevelt JD Beekman MAG van der Heyden L Ver Donck L Belardinelli S Richard G Antoons MA Vos for the CONTICA investigators 《British journal of pharmacology》2010,161(1):162-175
BACKGROUND AND PURPOSE
The high predisposition to Torsade de Pointes (TdP) in dogs with chronic AV-block (CAVB) is well documented. The anti-arrhythmic efficacy and mode of action of Ca2+ channel antagonists, flunarizine and verapamil against TdP were investigated.EXPERIMENTAL APPROACH
Mongrel dogs with CAVB were selected based on the inducibility of TdP with dofetilide. The effects of flunarizine and verapamil were assessed after TdP and in different experiments to prevent dofetilide-induced TdP. Electrocardiogram and ventricular monophasic action potentials were recorded. Electrophysiological parameters and short-term variability of repolarization (STV) were determined. In vitro, flunarizine and verapamil were added to determine their effect on (i) dofetilide-induced early after depolarizations (EADs) in canine ventricular myocytes (VM); (ii) diastolic Ca2+ sparks in RyR2R4496+/+ mouse myocytes; and (iii) peak and late INa in SCN5A-HEK 293 cells.KEY RESULTS
Dofetilide increased STV prior to TdP and in VM prior to EADs. Both flunarizine and verapamil completely suppressed TdP and reversed STV to baseline values. Complete prevention of TdP was achieved with both drugs, accompanied by the prevention of an increase in STV. Suppression of EADs was confirmed after flunarizine. Only flunarizine blocked late INa. Ca2+ sparks were reduced with verapamil.CONCLUSIONS AND IMPLICATIONS
Robust anti-arrhythmic efficacy was seen with both Ca2+ channel antagonists. Their divergent electrophysiological actions may be related to different additional effects of the two drugs. 相似文献189.
Health-care case management places pressure on decision makers to adopt treatment strategies that promote economic efficiency and hence profitability. Traditional costeffectiveness analysis (CEA), where the objective is to calculate cost-effectiveness ratios, can better inform decision making in markets where prices and efficacy vary widely. However, the threshold at which a given therapy becomes economically efficient relative to competing therapies is not evident from cost-effictiveness ratios alone.
OBJECTIVE: To illustrate the use of spatial techniques for identifying efficient treatment options, using statin therapy in secondary prevention of coronary heart disease (CHD) as a case study.
METHODS: We used a Markov model of CHD epidemiology and treatment to estimate cost-effectivness of 13 statin regimens versus no therapy in secondary prevention of CHD. Comparative efficacy was assessed using data from a recent trial (CURVES) that included these regimens. Patients were assumed to have a history of CHD with risk factors similar to those observed in the trial. CHD event risk was estimated using new subsequent-event risk equations from the Framingham Heart Study. Effectiveness was measured alternatively as gain in life expectancy and CHD events averted.
RESULTS: At usual starting doses, atorvastatin therapy provided the largest life expectancy gain and CHD event avoidance at the lowest cost per life-year gained ($12,900 and $23,400 for men and women, respectively), followed by simvastatin ($17,700 and $31,700), lovastatin ($18,800 and $33,700), pravastatin ($22,600 and $40,200), and fluvastatin ($23,800 and $42,000). Any desired level of effectiveness can be obtained at lowest cost with atorvastatin.
CONCLUSION: Economic efficiency is enhanced when atorvastatin is used to treat some or all patients requiring statin therapy in secondary prevention of CHD. 相似文献
OBJECTIVE: To illustrate the use of spatial techniques for identifying efficient treatment options, using statin therapy in secondary prevention of coronary heart disease (CHD) as a case study.
METHODS: We used a Markov model of CHD epidemiology and treatment to estimate cost-effectivness of 13 statin regimens versus no therapy in secondary prevention of CHD. Comparative efficacy was assessed using data from a recent trial (CURVES) that included these regimens. Patients were assumed to have a history of CHD with risk factors similar to those observed in the trial. CHD event risk was estimated using new subsequent-event risk equations from the Framingham Heart Study. Effectiveness was measured alternatively as gain in life expectancy and CHD events averted.
RESULTS: At usual starting doses, atorvastatin therapy provided the largest life expectancy gain and CHD event avoidance at the lowest cost per life-year gained ($12,900 and $23,400 for men and women, respectively), followed by simvastatin ($17,700 and $31,700), lovastatin ($18,800 and $33,700), pravastatin ($22,600 and $40,200), and fluvastatin ($23,800 and $42,000). Any desired level of effectiveness can be obtained at lowest cost with atorvastatin.
CONCLUSION: Economic efficiency is enhanced when atorvastatin is used to treat some or all patients requiring statin therapy in secondary prevention of CHD. 相似文献
190.
Impact of Breast Density Legislation on Breast Cancer Risk Assessment and Supplemental Screening: A Survey of 110 Radiology Facilities 下载免费PDF全文
Lina Nayak MD Kanae K. Miyake MD PhD Jessica W. T. Leung MD Elissa R. Price MD Yueyi I. Liu MD PhD Bonnie N. Joe MD PhD Edward A. Sickles MD William R. Thomas MD Jafi A. Lipson MD Bruce L. Daniel MD Jonathan Hargreaves MD R. James Brenner MD JD Lawrence W. Bassett MD Haydee Ojeda‐Fournier MD Karen K. Lindfors MD MPH Stephen A. Feig MD Debra M. Ikeda MD 《The breast journal》2016,22(5):493-500
Breast density notification laws, passed in 19 states as of October 2014, mandate that patients be informed of their breast density. The purpose of this study is to assess the impact of this legislation on radiology practices, including performance of breast cancer risk assessment and supplemental screening studies. A 20‐question anonymous web‐based survey was emailed to radiologists in the Society of Breast Imaging between August 2013 and March 2014. Statistical analysis was performed using Fisher's exact test. Around 121 radiologists from 110 facilities in 34 USA states and 1 Canadian site responded. About 50% (55/110) of facilities had breast density legislation, 36% of facilities (39/109) performed breast cancer risk assessment (one facility did not respond). Risk assessment was performed as a new task in response to density legislation in 40% (6/15) of facilities in states with notification laws. However, there was no significant difference in performing risk assessment between facilities in states with a law and those without (p < 0.831). In anticipation of breast density legislation, 33% (16/48), 6% (3/48), and 6% (3/48) of facilities in states with laws implemented handheld whole breast ultrasound (WBUS), automated WBUS, and tomosynthesis, respectively. The ratio of facilities offering handheld WBUS was significantly higher in states with a law than in states without (p < 0.001). In response to breast density legislation, more than 33% of facilities are offering supplemental screening with WBUS and tomosynthesis, and many are performing formal risk assessment for determining patient management. 相似文献